Related references
Note: Only part of the references are listed.First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2018)
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Peter R. Rhode et al.
CANCER IMMUNOLOGY RESEARCH (2016)
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
Bai Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
Evan Gomes-Giacoia et al.
PLOS ONE (2014)
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Marko Babjuk et al.
EUROPEAN UROLOGY (2013)
The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity
Hing C. Wong et al.
ONCOIMMUNOLOGY (2013)
The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Gu,rin (BCG) immunotherapy for urothelial carcinoma of the bladder
Henry M. Rosevear et al.
CANCER AND METASTASIS REVIEWS (2009)
Novel Human Interleukin-15 Agonists
Xiaoyun Zhu et al.
JOURNAL OF IMMUNOLOGY (2009)
History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story
Harry W. Herr et al.
JOURNAL OF UROLOGY (2008)
Molecular credentialing of rodent bladder carcinogenesis models
Paul D. Williams et al.
NEOPLASIA (2008)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Thomas A. Waldmann
NATURE REVIEWS IMMUNOLOGY (2006)
Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression
JH Zhou et al.
CANCER GENE THERAPY (2002)
Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer
M Yamashita et al.
CANCER GENE THERAPY (2002)
Interleukin-2 and interleukin-15: immunotherapy for cancer
TA Fehniger et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome
HW Herr
JOURNAL OF UROLOGY (2000)
Share Paper
